Fibroblast-tumor cell signaling limits HER2 kinase therapy response via activation of MTOR and antiapoptotic pathways [Medical Sciences]

Despite the implementation of multiple HER2-targeted therapies, patients with advanced HER2+ breast cancer ultimately develop drug resistance. Stromal fibroblasts represent an abundant cell type in the tumor microenvironment and have been linked to poor outcomes and drug resistance. Here, we show that fibroblasts counteract the cytotoxic effects of HER2 kinase-targeted...

Source: Proceedings of the National Academy of Sciences - July 13, 2020 Category: Science Authors: Ioannis K. Zervantonakis, Matthew D. Poskus, Alexis L. Scott, Laura M. Selfors, Jia-Ren Lin, Deborah A. Dillon, Shailja Pathania, Peter K. Sorger, Gordon B. Mills, Joan S. Brugge Tags: Biological Sciences Source Type: research